Single-Use Bioreactor Market Forecasted to Reach $9.58 Billion by 2031

The surge in demand is largely fueled by the biopharmaceutical sector's increasing focus on process intensification and the rapid scaling of cell and gene therapies. As companies look to reduce contamination risks and shorten facility changeover times, single-use bioreactor systems have become the industry standard for both clinical and commercial production.

North America currently commands the largest market share, bolstered by a robust ecosystem of contract development and manufacturing organizations (CDMOs) and high levels of investment in biologics research. While batch and fed-batch methods remain prevalent, the perfusion and continuous process segments are expected to see the fastest growth, as they offer higher volumetric productivity and improved product quality. Manufacturers are now prioritizing integrated platforms that allow for seamless technology transfer from the laboratory to large-scale commercial operations, while simultaneously addressing technical challenges related to supply chain resilience and plastic waste management.